Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $159.63 USD
Change Today -3.95 / -2.41%
Volume 2.3M
AMGN On Other Exchanges
Hong Kong
Sao Paulo
As of 12:24 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/15 - $173.60
52 Week Low
05/27/14 - $114.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.4M
Executive Vice President of Operations
Total Annual Compensation: $943.0K
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $899.9K
Compensation as of Fiscal Year 2014.

amgen inc (AMGN) Key Developments

Amgen's Cholesterol Treatment Edges Closer to EMA Approval

Amgen reported a panel to the European Medicines Agency (EMA) has recommended for approval its cholesterol treatment Repatha. The Committee for Medicinal Products for Human Use (CHMP) based its approval on the drug on data from ten Phase III trials. The studies evaluated the safety and efficacy of Repatha in patients with elevated cholesterol. The European Commission traditionally follows the panel's recommendations and issues a final decision within three months. Repatha is a representative of a new kind of cholesterol treatments that potentially may reduce heart attack risks. It contains an inhibitor that binds with a protein that usually degrades low-density lipoprotein receptors, thus reducing the liver's ability to remove the so-called bad cholesterol from the blood. Amgen has been engaged in a tight race with France' Sanofi which is also developing a drug of this kind together with US Regeneron Pharmaceuticals Inc. Neither of the companies has received an approval from the US Food and Drug Agency, but it seems Amgen will be the first to win market approval in the EU.

Amgen Appoints Jonathan P. Graham as Senior Vice President, General Counsel and Secretary, Effective July 13, 2015

Amgen announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July 13, 2015. He will be responsible for Amgen's legal operations, reporting to Robert A. Bradway, chairman and chief executive officer. Graham will succeed David J. Scott who is retiring August 31, 2015. Graham joins Amgen from Danaher Corporation, where he has served as senior vice president and general counsel, responsible for all legal, governance, regulatory, risk, and compliance matters. Previously, Graham was vice president, litigation and legal policy at General Electric Company and a partner at Williams & Connolly LLP.

Amgen Announces First Results from its Global Phase 2

Amgen announced the first results from its global Phase 2, double-blind, placebo-controlled study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine. The study met its primary endpoint of reducing monthly mean migraine days compared with placebo. The data were presented at the 17thCongress of the International Headache Society (IHC 2015) in Valencia, Spain. AMG 334 is a fully human monoclonal antibody under investigation for the prevention of migraine by inhibiting the calcitonin gene-related peptide (CGRP) receptor that is believed to transmit signals that can cause incapacitating pain. In the trial, 483 patients were randomized to subcutaneous monthly placebo or AMG 334 (7 mg, 21 mg or 70 mg) in a 3:2:2:2 ratio, respectively. Patients had a mean baseline of 8.7 migraine days per month. The primary endpoint was the change from baseline in monthly migraine days at week 12. Patients randomized to the 70 mg dose group observed a statistically significant 3.4-day reduction in monthly migraine days compared with 2.28 days observed in the placebo group (p=0.021).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $159.70 USD -3.88

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.89 USD +1.41
Bristol-Myers Squibb Co $67.57 USD -0.73
Eli Lilly & Co $74.25 USD -0.05
Medtronic PLC $77.07 USD -0.75
Novo Nordisk A/S kr390.10 DKK +2.10
View Industry Companies

Industry Analysis


Industry Average

Valuation AMGN Industry Range
Price/Earnings 22.1x
Price/Sales 6.1x
Price/Book 4.7x
Price/Cash Flow 21.8x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at